我很难回答, 因为我不是专家.
我这样回答:
一个台湾研究显示:
1. 100公里的马拉松，发现肝脏，肌肉和炎症乙肝病毒携带者和非携带者之间的所有生物标记物无统计学差异。他们认为，在100公里耐力赛, 非携带者相比, 乙肝病毒携带者不具有更高的风险,肝功能障碍，肌肉分解，炎症反应.
found no statistical difference in all biomarkers of liver, muscle, and inflammation between HBV carriers and noncarriers. They suggest that HBV carriers do not have higher risks of liver function impairment, muscle breakdown, and inflammatory response compared with noncarriers in the 100-km endurance race.
2. 7天的超马拉松比赛, 发现，相比非携带者，乙肝病毒携带者总胆红素水平, 有血清ALT，AST，总胆红素水平。越高
found that that there were higher serum ALT, AST, and total bilirubin levels in the HBV carriers compared with the noncarriers in a 7-day ultramarathon race. http://www.jcma-online.com/artic ... %2900004-6/fulltext
